Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).
Masuda J, Sakai H, Tsurutani J, Tanabe Y, Masuda N, Iwasa T, Takahashi M, Futamura M, Matsumoto K, Aogi K, Iwata H, Hosonaga M, Mukohara T, Yoshimura K, Imamura CK, Miura S, Yamochi T, Kawabata H, Yasojima H, Tomioka N, Yoshimura K, Takano T.
Masuda J, et al. Among authors: kawabata h.
J Immunother Cancer. 2023 Sep;11(9):e007126. doi: 10.1136/jitc-2023-007126.
J Immunother Cancer. 2023.
PMID: 37709297
Free PMC article.
Clinical Trial.